|
Market Closed -
NSE India S.E.
15:05:09 20/08/2026 +04
|
5-day change | 1st Jan Change | ||
| 1,904.00 INR | +0.21% |
|
-1.45% | +10.72% |
| 08-05 | CRISIL Keeps AAA Rating on Sun Pharmaceutical's Bank Facilities | MT |
| 07-31 | Sun Pharmaceutical Industries Limited, Q1 2027 Earnings Call, Jul 31, 2026 |
| Market Cap | 4,559B 47.69B 40.91B 38.2B 35.05B 65.91B 67B 451B 177B 2,286B 179B 175B 7,559B | P/E 2027 * |
35.1x | P/E 2028 * | 29.7x |
|---|---|---|---|---|---|
| Enterprise Value | 4,280B 44.78B 38.41B 35.86B 32.91B 61.88B 62.9B 423B 166B 2,146B 168B 164B 7,097B | EV / Sales 2027 * |
6.57x | EV / Sales 2028 * | 5.78x |
| Free-Float |
44.39% | Yield 2027 * |
0.9% | Yield 2028 * | 1.05% |
Last Transcript: Sun Pharmaceutical Industries Ltd.
| 1 day | +0.21% | ||
| 1 week | -1.45% | ||
| Current month | -4.35% | ||
| 1 month | -2.68% | ||
| 3 months | +1.26% | ||
| 6 months | +10.42% | ||
| Current year | +10.72% |
| 1 week | 1,868.3 |  | 1,949.8 |
| 1 month | 1,868.3 | | 2,046.9 |
| Current year | 1,583.7 | | 2,046.9 |
| 1 year | 1,548 | | 2,046.9 |
| 3 years | 1,068.35 | | 2,046.9 |
| 5 years | 733.7 | | 2,046.9 |
| 10 years | 312 | | 2,046.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Chief Executive Officer | 59 | 01/09/2025 | |
| Director of Finance/CFO | 58 | 01/07/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | - | |
| Director/Board Member | 59 | 01/09/2025 | |
| Director/Board Member | 73 | 25/05/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.21% | -1.45% | +16.59% | +67.40% | 47.69B | |
| +4.52% | +1.33% | +56.08% | +133.25% | 39.96B | |
| +1.13% | -1.43% | -6.99% | +16.55% | 12.02B | |
| +0.29% | -5.11% | +12.65% | +69.61% | 11.53B | |
| 0.00% | +0.19% | +30.00% | +147.62% | 9.18B | |
| -0.39% | -1.15% | +19.93% | +39.54% | 7.53B | |
| +0.87% | +2.65% | +46.27% | -10.72% | 7.29B | |
| +3.85% | +0.56% | +21.25% | +201.00% | 6.63B | |
| -3.28% | -4.68% | -33.43% | +20.83% | 5.57B | |
| -1.06% | +1.22% | +36.33% | +104.47% | 4.83B | |
| Average | +0.61% | -1.78% | +19.87% | +78.95% | 15.22B | |
| Weighted average by Cap. | +1.40% | -2.11% | +26.19% | +85.84% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 651B 6.81B 5.84B 5.45B 5B 9.41B 9.57B 64.36B 25.2B 326B 25.57B 25.01B 1,079B | 729B 7.62B 6.54B 6.11B 5.6B 10.54B 10.71B 72.06B 28.22B 365B 28.63B 28B 1,208B |
| Net income | 130B 1.36B 1.17B 1.09B 1B 1.88B 1.91B 12.87B 5.04B 65.28B 5.11B 5B 216B | 154B 1.61B 1.38B 1.29B 1.19B 2.23B 2.27B 15.25B 5.97B 77.33B 6.06B 5.93B 256B |
| Net Debt | -279B -2.92B -2.5B -2.34B -2.15B -4.03B -4.1B -27.59B -10.8B -140B -10.96B -10.72B -463B | -349B -3.65B -3.13B -2.93B -2.68B -5.05B -5.13B -34.53B -13.52B -175B -13.72B -13.42B -579B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 20/08/26 | ₹1,904.00 | +0.21% | 893,691 |
| 19/08/26 | ₹1,900.00 | +1.33% | 1,566,692 |
| 18/08/26 | ₹1,875.10 | -0.37% | 1,819,169 |
| 17/08/26 | ₹1,882.00 | -2.49% | 1,893,086 |
| 14/08/26 | ₹1,930.00 | -0.10% | 881,282 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SUNPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
